These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 35462358)

  • 41. Dupilumab use in atopic dermatitis and beyond in skin diseases.
    Fourzali K; Golpanian RS; Yosipovitch G
    Immunotherapy; 2020 Dec; 12(17):1221-1235. PubMed ID: 32892674
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Combination treatment with monoclonal antibodies: Dupilumab and ustekinumab for the treatment of severe atopic dermatitis and Crohn disease.
    Alegre-Bailo A; Sánchez-Gilo A; Gonzalo González I; Vicente Martín FJ
    Australas J Dermatol; 2024 Feb; 65(1):63-66. PubMed ID: 37929636
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Successful Combination of Systemic Agents for the Treatment of Atopic Dermatitis Resistant to Dupilumab Therapy.
    Gori N; Chiricozzi A; Malvaso D; D'Urso DF; Caldarola G; De Simone C; Peris K
    Dermatology; 2021; 237(4):535-541. PubMed ID: 33477153
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Patch Testing in Patients With Severe Atopic Dermatitis Treated With Dupilumab: A Multicentric Approach in Spain.
    Docampo-Simón A; Sánchez-Pujol MJ; Pastor-Nieto MA; Giménez-Arnau A; Rodríguez-Serna M; Serra-Baldrich E; Miquel J; Sánchez-Pérez J; Sanz-Sánchez T; Zaragoza-Ninet V; Sánchez-Pedreño P; Carrascosa JM; Gatica-Ortega ME; Fernández-Redondo V; Córdoba-Guijarro S; González-Pérez R; Silvestre JF
    Dermatitis; 2023; 34(4):315-322. PubMed ID: 37001174
    [No Abstract]   [Full Text] [Related]  

  • 45. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study.
    Deleuran M; Thaçi D; Beck LA; de Bruin-Weller M; Blauvelt A; Forman S; Bissonnette R; Reich K; Soong W; Hussain I; Foley P; Hide M; Bouaziz JD; Gelfand JM; Sher L; Schuttelaar MLA; Wang C; Chen Z; Akinlade B; Gadkari A; Eckert L; Davis JD; Rajadhyaksha M; Staudinger H; Graham NMH; Pirozzi G; Ardeleanu M
    J Am Acad Dermatol; 2020 Feb; 82(2):377-388. PubMed ID: 31374300
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Treatment-resistant adult atopic dermatitis].
    Esteve-Martínez A; García-Rabasco A; Miralles J; de-la-Cuadra-Oyanguren J
    Actas Dermosifiliogr; 2011 Dec; 102(10):821-2. PubMed ID: 21820642
    [No Abstract]   [Full Text] [Related]  

  • 47. Dupilumab is very effective in a large cohort of difficult-to-treat adult atopic dermatitis patients: First clinical and biomarker results from the BioDay registry.
    Ariëns LFM; van der Schaft J; Bakker DS; Balak D; Romeijn MLE; Kouwenhoven T; Kamsteeg M; Giovannone B; Drylewicz J; van Amerongen CCA; Delemarre EM; Knol EF; van Wijk F; Nierkens S; Thijs JL; Schuttelaar MLA; de Bruin-Weller MS
    Allergy; 2020 Jan; 75(1):116-126. PubMed ID: 31593343
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dupilumab treatment in two patients with severe allergic contact dermatitis caused by sesquiterpene lactones.
    Ruge IF; Skov L; Zachariae C; Thyssen JP
    Contact Dermatitis; 2020 Aug; 83(2):137-139. PubMed ID: 32243595
    [No Abstract]   [Full Text] [Related]  

  • 49. Off-label use of dupilumab for pediatric patients with atopic dermatitis: A multicenter retrospective review.
    Igelman S; Kurta AO; Sheikh U; McWilliams A; Armbrecht E; Jackson Cullison SR; Kress DW; Smith A; Castelo-Soccio L; Treat J; Boothe WD; Diaz LZ; Levy ML; Patel A; Lee LW; Fraile-Alonso MC; Antaya RJ; Shah S; Kittler N; Arkin L; Siegfried E
    J Am Acad Dermatol; 2020 Feb; 82(2):407-411. PubMed ID: 31606479
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Apremilast 30 mg twice daily combined with dupilumab for the treatment of recalcitrant moderate-to-severe atopic dermatitis.
    Cunningham KN; Alsukait S; Cohen SR; Learned C; Gao DX; Kachuk C; Dumont N; Zipeto A; Rosmarin D
    J Eur Acad Dermatol Venereol; 2023 Jun; 37(6):e765-e767. PubMed ID: 36688247
    [No Abstract]   [Full Text] [Related]  

  • 51. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS).
    Wollenberg A; Beck LA; Blauvelt A; Simpson EL; Chen Z; Chen Q; Shumel B; Khokhar FA; Hultsch T; Rizova E; Rossi AB; Graham NMH; Pirozzi G; Lu Y; Ardeleanu M
    Br J Dermatol; 2020 May; 182(5):1120-1135. PubMed ID: 31407311
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Real-life long-term efficacy of dupilumab in adults with moderate to severe atopic dermatitis: Results of a cohort study.
    Guédon C; Tauber M; Linder C; Paul C; Shourick J
    Ann Dermatol Venereol; 2023 Sep; 150(3):215-216. PubMed ID: 37598014
    [No Abstract]   [Full Text] [Related]  

  • 53. Short-Term Evaluation of the Real-World Efficacy and Safety of Dupilumab for the Treatment of Moderate-to-Severe Atopic Dermatitis: A Canadian Multicenter Retrospective Cohort Study [Formula: see text].
    Jo CE; Georgakopoulos JR; Ladda M; Ighani A; Mufti A; Drucker AM; Piguet V; Yeung J
    J Cutan Med Surg; 2020; 24(5):468-473. PubMed ID: 32442020
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Elevation of peripheral blood eosinophils during dupilumab treatment for atopic dermatitis is associated with baseline comorbidities and development of facial redness dermatitis and ocular surface disease.
    Ferrucci S; Angileri L; Tavecchio S; Fumagalli S; Iurlo A; Cattaneo D; Marzano AV; Maronese CA
    J Dermatolog Treat; 2022 Aug; 33(5):2587-2592. PubMed ID: 35261333
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry.
    Ariëns LFM; Bakker DS; Spekhorst LS; Van der Schaft J; Thijs JL; Haeck I; Flinterman AE; Kamsteeg M; Schuttelaar MLA; De Bruin-Weller MS
    Acta Derm Venereol; 2021 Oct; 101(10):adv00573. PubMed ID: 34396421
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dupilumab for Allergic Contact Dermatitis: An Overview of Its Use and Impact on Patch Testing.
    Johnson H; Adler BL; Yu J
    Cutis; 2022 May; 109(5):265-267. PubMed ID: 35856769
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Improvement of alopecia areata with Dupilumab in a patient with severe atopic dermatitis and review the literature.
    Magdaleno-Tapial J; Valenzuela-Oñate C; García-Legaz-Martínez M; Martínez-Domenech Á; Pérez-Ferriols A
    Australas J Dermatol; 2020 May; 61(2):e223-e225. PubMed ID: 31766073
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of Residual Facial Dermatitis during Dupilumab Therapy: A Retrospective Chart Review to Delineate the Potential Role of Expanded Series Patch Testing.
    Ashbaugh AG; Murase EM; Raffi J; Botto N; Murase JE
    Dermatitis; 2022 Jan-Feb 01; 33(1):51-61. PubMed ID: 35029349
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Psoriasiform dermatitis during dupilumab treatment for moderate-to-severe atopic dermatitis in children.
    Parker JJ; Sugarman JL; Silverberg NB; Gonzalez ME; Ramien ML; Teng JMC; Paller AS
    Pediatr Dermatol; 2021 Nov; 38(6):1500-1505. PubMed ID: 34647354
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effectiveness of dupilumab on chronic lymphedema associated hand dermatitis.
    Bouderbala Y; Quere I; Guillemard S; Dereure O; Raison-Peyron N
    Contact Dermatitis; 2024 Nov; 91(5):448-450. PubMed ID: 39031034
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.